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Objective. This study is to investigate the role of the CIKs cocultured with K-ras-DCs in killing of pancreatic cancer cell lines,
PANC-1 (K-ras+) and SW1990 (K-ras−). Methods. CIKs induced by IFN-γ, IL-2, and anti-CD3 monoantibody, K-ras-DCCIKs
obtained by cocultivation of k-ras-DCs and CIKs. Surface markers examined by FACS. IFN-γ IL-12 ,CCL19 and CCL22 detected
by ELISA. Proliferation of various CIKs tested via 3H-TdR. Killing activities of k-ras-DCCIKs and CTLs examined with 125IUdR.
Results.CD3 +CD56+ andCD3+CD8+ werehighlyexpressedbyK-ras-DCCIKs.Initssupernatant,IFN-γ,IL-12,CCL19andCCL22
were signiﬁcantly higher than those in DCCIK and CIK. The killing rate of K-ras-DCCIK was greater than those of CIK and CTL.
CTL induced by K-ras-DCs only inhibited the PANC-1 cells. Conclusions. The k-ras-DC can enhance CIK’s proliferation and
increase the killing eﬀect on pancreatic cancer cell. The CTLs induced by K-ras-DC can only inhibit PANC-1 cells. In this study,
K-ras-DCCIKs also show the speciﬁc inhibition to PANC-1 cells, their tumor suppression is almost same with the CTLs, their total
tumor inhibitory eﬃciency is higher than that of the CTLs.
1.Introduction
Theincidenceofpancreaticcancerhasshownaclearuptrend
[1], and the prognosis in last 20 years has not yet im-
proved [2]. Current immunotherapies for pancreatic cancer
mainly include active speciﬁc immunotherapy, monoclonal
antibody-directed therapy, cytokine therapy, and adoptive
cellularimmunotherapy[3].Theaimofthisstudyistoinves-
tigate the role of the cytokine-induced killer cells (CIKs) coc-
ulturedwithdendriticcells(DCs)andpulsedwithK-ras(12-
Val) mutant peptide in the killing of pancreatic cancer cell
lines, PANC-1 and SW1990, both in vivo and in vitro.
Dendritic cell (DC) is an antigen-presenting cell, whose
function is strongest in the body. They play a role as the
bridge and the pivot in the interaction of tumor cells and T
lymphocytes [4]. The killer cells induced by cytokines IFN-
γ and IL-2 and anti-CD3 monoclonal antibody (cytokine-
induced killer, CIK) non-MHC-restrictive cytotoxic T lym-
phocytes, which kills tumor cells via recognition to a series
of related ligands expressed in tumor surface [5, 6]. So far,
these cells are considered to have the fastest proliferation, the
strongest tumor cytotoxicity, and the most extensive range of
tumorkilling.Hence,theyaretheﬁrstchoicefortheadoptive
immunotherapyoftumors[7].CocultivationofCIKandDC
pulsed with K-ras (12-Val) protein peptide, which contains a
speciﬁc mutation site, can increase the existence of antigen-
speciﬁc CTL subsets and DC-induced speciﬁc CTL activity.
Meanwhile, strengthening CIK cell proliferation can further
be expected to improve the scope and eﬀects of antitumor
immunotherapy. As of now, the research on synergy therapy
for pancreatic cancer with the K-ras antigen-allergized DC
and CIK has not yet been reported.
2.MaterialsandMethods
2.1. Materials. rhIL-2 and GM-CSF were purchased from
R&D Inc. (USA). IL-4, TNF-4, and IFN-γ were acquired
from Peprotech Inc.. Fetal bovine serum (FBS) and cell2 Clinical and Developmental Immunology
medium RPMI1640 were sourced from Sigma-Aldrich Co,
Ltd (USA). Lymphocyte separation medium Ficoll and nor-
mal human AB serum were purchased from TBD Inc. (Tian-
jin, China). Mouse anti-human CD3 (FITC labelled) mon-
oclonal antibody, mouse anti-human CD56 (PE labelled)
monoclonal antibody, mouse anti-human CD8 (PE labelled)
monoclonal antibody, and mouse anti-human CD3 (unla-
belled) monoclonal antibody were bought from eBioscience
Co, Ltd. Mouse anti-human CD80-PE monoclonal antibody,
mouse anti-human CD83-PE monoclonal antibody, mouse
anti-human CD86-PE monoclonal antibody, mouse anti-
human CD40-FITC monoclonal antibody, and mouse anti-
human CD1a-FITC monoclonal antibody were all products
of Immunotech Co, Ltd (France). CCL19 and CCL22 ELISA
kitswerefromADLInc..Mouseanti-humanFascin-1mono-
clonalantibodyandgoatanti-mouseIgGsecondaryantibody
were from Santa Cruz Co, Ltd. Cell strains, PANC-1 and
SW1990, are available from ATCC. K-ras mutant epitope
peptide KLVVVGAVGVGKSALTC was synthesized by SBS
Genetech., Ltd.. Female nude mice (BALB/c, 5–8 weeks of
age) raised under SPF circumstance were purchased from
the Shanghai Laboratory Animal Center, Chinese Academy
of Sciences.
2.2. Preparation of DCs and CTLs. 50mL of peripheral
blood was sterilely collected from a healthy adult volunteer.
Peripheral blood mononuclear cells (PBMCs) were then
obtained by lymphocyte separation medium, washed twice
with RPMI1640, then diluted to 2 ×106/mL with RPMI1640
containing 10% (V/V) human AB serum. Subsequently,
these cells were transferred into culture ﬂasks and cultured
for 1-2 hours. Nonadherent cells were harvested as the pro-
genitor of cytokine-induced killer (CIK). The remaining ad-
herentcellswereculturedbyaddingDCmedium(containing
0.2mg/L GM-CSF, 1000U/mL rhIL-4), and exchanged half
amount of DC medium in the next day until 7 days. K-ras
mutant epitope peptide was then added into the culture on
the 7th day. After 24 hours of cultivation, the culture was
induced by adding TNF-α (10ng/mL) over the following 2
days. Lymphocytes at the ﬁnal density of 2 × 105/well were
then mixed with the k-ras antigen-pulsed DC at 2 ×104/well
in 96-well plate, respectively. Under 37◦C and 5% CO2,C T L
cells were cultured for 5 days for induction by the speciﬁc
antigen after which it was ready for use [8].
2.3. CIK Cell Induction and Proliferation. The density of the
harvested nonadherent cells was adjusted to 1×106/mL with
PRMI1640medium.AfteraddingIFN-γ 1000U/mL,thecul-
ture was cultivated under the condition of 37◦C and 5% CO2
for 24 hours, when CD3 monoclonal antibody (50ng/mL)
and rhIL-2 (1000u) was added. Subsequently, these cells
exchanged half the amount of medium every three days and
supplemented CD3 monoclonal antibody and rhIL-2 [9].
2.4. Culture of DCCIKs and Detection for their Cytokine
and Proliferation Activity. In 96-well plates, CIKs with
density 2 × 105/well were mixed with the antigen-unpulsed
DCs and K-ras peptide antigen-allergized DCs, which had
been induced and cultured for 9 days, at the density of
2 × 104/well.ThecellmixtureswerethenculturedwithCIK
mediumundertheconditionof37◦Cand5%CO2 for5days.
Afteradding 3H-TdR(37kBq/well),thesecellswerethencul-
tured for another 12 hours. After 12 hours, the cell mixtures
were collected and examined by verifying their cpm values
withaliquidscintillationcounterandbycountingtheirstim-
ulationindex(SI):SI=(cpmofexperimentalgroup−cpmof
background)/(cpm of control group − cpm of background).
The proliferation of CIKs, DCCIKs, and K-ras-DCCIKs was
observed. Moreover, IL-12 and IFN-γ in the supernatants of
the cells cultured for 14 days were tested by ELISA.
2.5. Morphologic Observation and Cellular Phenotype Analysis
of DCs and DCCIKs. Morphological changes of DCs and
DCCIKs were observed by scanning and transmission elec-
tron microscopy after which, the DCs cultured for 7 days
and the K-ras pulsed DCs cultured for 9 days were harvested.
Using FACS, their phenotype molecules, CD1a, CD80,
CD83, CD86, and HLA-DR, were measured and recorded.
Afterward, the K-ras-DCs that were originally cultured for 9
days were co-cultivated with CIKs for 5 days. Subsequently,
CIKs,DCCIKs,andK-ras-DCCIKswerecollectedatthe14th
day of the cultivation, and the expression of surface mark-
ers, CD3, CD3+CD56+, and CD3+CD8+, was examined and
recorded.
2.6. Detection of CCL19, CCL22, and Fascin-1 of k-Ras-
DCCIKs. CIKcoculturedwithDCandDCpulsedwithK-ras
peptide at day 9th, the supernatants of the CIK, DCCIK and
K-ras-DCCIK were collected at time points of preloading, 6
hours, 12 hours, 24 hours, and 48 hours, respectively. The
CCL19 and CCL22 contents (absorbance) in the superna-
tants were tested separately by ELISA, three repeats for each
group.Furthermore,CIKs,DCCIKs,andK-ras-DCCIKsthat
h a db e e nc u l t u r e df o r1 4d a y sw e r eh a r v e s t e df o rp r o t e i n
extraction. Fascin-1 protein samples of each group were
separated by SDS-PAGE and detected by western blot. β-
actin was used as an internal reference. Mouse anti-human
Fascin-1 monoclonal antibody was used as primary antibody
(1:3000), and goat anti-mouse IgG polyclonal antibody was
used as secondary antibody (1:5000).
2.7. Killing Activity of Diﬀerent CIKs and CTLs to PANC-
1[ 10] and SW1990 Pancreatic Cancer Cells. The K-ras-
DCCIKs, DCCIKs, CIKs, and CTLs cultured for 14 days were
used as eﬀector cells and PANC-1 and SW1990 as target
cells. 1 × 106 tumor cells in log phase were collected and
added 5μCi 125I-UdR and ﬁnal concentration of 5mol 5-
ﬂuorouracil. The cells were incubated in suspension culture
under the condition of 37◦C and 5% CO2 for 2 hours. After
washing three times with IMDM medium to eliminate the
unlabelled 125I-UdR, the tumor cells were counted with γ-
counter. Only the cells that had average labelling yield above
1 cpm were used as target cells. Then, the target cells were
adjusted with IMDM medium containing 10% FCS to the
density of 5 × 105/mL to be ready for use. In accordance
with diﬀerent eﬀector-target ratio (1:6.25, 1:12.5, 1:25,
1:50), the eﬀector cells were mixed with the target cells and
supplemented with medium to yield one milliliter (threeClinical and Developmental Immunology 3
repeats). Meanwhile, the control group of target cells was
usedtotestthespontaneousreleaserate.Aftercentrifugation
of 1000r/min for 3 minutes, the eﬀector-target cell mixtures
were cultured for 12 more hours. Finally, the cell mixtures
were centrifugated at 2000r/min for 5 minutes and tested
for their cpm values. The cytotoxic activity is shown with
125I-UdR release percentage, which is calculated according to
the following formula: 125I-UdR release percentage = (cpm
value of experimental group − cpm value of spontaneous
release group)/(cpm value of maximum release − cpm value
of spontaneous release group).
2.8. Animal Experiment. PANC-1 and SW1990 in log phase
were prepared to 1 × 107/mL cell suspension. Every female
BALB/c nude mice of 5–8 weeks old were subcutaneously
inoculated in their backs with 0.2mL of the suspension to
build the tumor-bearing mouse model. At the 10th day after
inoculation,themicewererandomlydividedintoﬁvegroups
(10 mice per group). Experimental group (I) Group k-ras-
DCCIK, k-ras-DCCIKs, were used for every injection. (II)
Group DCCIK, DCCIKs were used. (III) Group CIK, CIKs
were used. (IV) Group CTL, CTLs induced with k-ras-DCs,
were used. (V) Group saline control, saline water was used.
2 × 106 CTLs and various CIKs were injected intratumor
every two days, respectively, ten injections in total. Before
every injection, the long diameter (L) and the short diameter
(S) of the tumors were measured. And tumor sizes were esti-
mated by formula: V = (L×S2)/2 .T h eﬁ n a ls u r v i v a lt i m eo f
each group was observed.
2.9. Statistical Analysis. The statistic software SPSS 16.0 was
used for data analysis, and Lab-wiok4.6 was used for analysis
of western blot results. Measurement data were indicated
with mean ± standard deviation. And the original data were
tested via homogeneity of variance, and then used for t-test
and variance analysis. The diﬀerences were deemed to show
statistical signiﬁcance when P<0.05. And the ﬁnal statistic
values of diﬀerent samples are the gray value ratios of the
samples and their relevant internal references.
3. Results
3.1. Morphological Observation of DC and CIK
3.1.1. Morphological Observation of K-ras (12-Val) Mutant
Peptide-Pulsed DC. After being pulsed with K-ras (12-Val)
mutant peptide, DCs showed larger soma with plenty of
dendritic bulges on their surfaces (Figure 1(a)) under scan-
ningmicroscopy.TheDCsalsoshowedirregularshape.From
the microscopy, large and long dendritic bulges and small
ones were observed on the surface. In the DCs, organelles
are abundant. Many mitochondria and rough endoplasmic
reticulum were present in the image, though less lysosomes
were observed (Figure 1(b)).
3.1.2. Morphological Observation of CIK and DCCIK. Under
microscopy, CIKs showed cluster-like growth. And after 3
days of incubation, CIKs’ cell masses gradually multiplied
and became larger. On the 7th day, the cells began to look
5 μm
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(b)
20 μm
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Figure 1: The morphological changes of k-ras pulsed DC and K-
ras-DCCIK under scanning and transmission electron microscopy
(experiment 2.5). DCs pulsed with K-ras mutant peptide show
a larger soma, and plenty of dendritic bulges on their surfaces
(Figure 1(a)). Under transmission electron microscopy, DCs show
irregular-shape, large, and long dendritic bulges on their surfaces.
In the DCs, organelles are abundant, and many mitochondria and
rough endoplasmic reticulum can be seen, but less lysosome are
present (Figure 1(b)). Coculture of DCs and CIKs for 14 days; un-
der scanning electron microscopy, cells aggregated together to form
many cell masses, on the surfaces of which there were plenty of
dendritic bulges (Figure 1(c)).
rounded with regular shapes. After DCs and CIKs were co-
cultured for 14 days, the cells aggregated together to form
many cell masses, on the surfaces of which there were plenty
of dendritic bulges (Figure 1(c)).
3.2. Cellular Phenotype Detection of DC, CIK, and DCCIK.
The expression levels of CD1a, CD80, CD83, and HLA-DR
of K-ras-DC were higher than those of the unpulsed DC4 Clinical and Developmental Immunology
Table 1: Surface marker of DCs induced by diﬀerent antigens (%, X ±SD, n = 6).
Groups CD1a CD80 CD83 CD86 HLA-DR
DC 22.6 ±3.64 9 .4 ±3.23 8 .5 ±4.67 2 .6 ±5.66 6 .5 ±4.6
DC(K-ras+ peptide,10μg/mL) 35.1 ±4.36 2 .2 ±5.85 1 .1 ±4.97 4 .4 ±5.28 2 .4 ±4.4
Note: DC (K-ras+ peptide, 10μg/mL) versus DC, P<0.05 except CD86.
Table 2: Surface marker of CIK and DCCIK induced by antigens
(%, X ±SD, n = 6).
Groups CD3 CD3+CD56+ CD3+CD8+
CIK 66.34 ±4.54 34.18 ±2.63 56.38 ±4.87
DCCIK 71.4 ±55.26 39.21 ±3.12 54.23 ±4.14
K-ras-DCCIK 87.53 ±6.02 57.43 ±4.34 68.65 ±3.32
Note: DCCIK pulsed with K-ras peptides versus CIK and DCCIK, (P<
0.05).
group (P<0.05). However, no signiﬁcant diﬀerence was ob-
served with tCD86 expressions among the groups (P>0.05)
(Table 1.). This demonstrated that the dendritic cells can
express the mature surface molecules after antigen allergiza-
tion. After cocultivation, the K-ras-DCCIK population can
express CD3+CD8+ and CD3+CD56+ at levels which were
signiﬁcantlyhigherthanthoseoftheunpulsedDCCIKgroup
and the CIK group (P<0.05) (Table 2).
3.3. ELISA Test for Chemokine, CCL19 and CCL22, and
Western Blot Analysis for Cytoskeletal Protein, Fascin-1. The
CCL19 and CCL22 expression levels in the culture super-
natants of group K-ras-DCCIK and group DCCIK were
universally higher than those of group CIK except for pre-
loading and the ﬁrst 6-hour point. Moreover, the CCL19 and
CCL22 levels in group K-ras-DCCIK and group DCCIK also
showed uptrend with time. After testing at 12 hours, their
levels increased more signiﬁcantly (P<0.01). While at the
same time, CCL19 and CCL22 expression levels in group
CIK showed no apparent increase. Finally, the comparison
of the chemokine expression between group K-ras-DCCIK
and group DCCIK also has statistical diﬀerence (P<0.05)
(Figures 2(a) and 2(b)).
3.3.1. Western Blot Analysis for Cytoskeletal Protein, Fascin-1.
The result is shown in Figures 3(a), 3(b), and 3(c), which
demonstrates the fascin-1 expressions in DCCIK, CIK, and
K-ras-DCCIK (cultured for 14 days). After protein bands
analysis with Lab-wiok4.6, it is shown that the expression
of the cytoskeletal protein, fascin-1, in K-ras-DCCIK had
increased signiﬁcantly. Compared with group DCCIK and
group CIK, the diﬀerences showed statistical signiﬁcance
(P<0.01). Furthermore, the comparison between DCCIK
and CIK shows that the diﬀerence was also signiﬁcant (P<
0.05). The gray values of the reference protein bands are
almost equal. This proved that β-actin can be stably express-
ed in the cells. The results demonstrated that K-ras mutant
antigen peptide can facilitate the migration activity of
DCCIKs.
3.4. Proliferation Activity Test of CIK and DCCIK. CIKs
began proliferating from the third day of culture, and the cell
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Figure 2: The absorbances of CCL19 and CCL22 at diﬀerent time
points (experiment 2.6). The expression of CCL19 and CCL22 in
group K-ras-DCCIK and DCCIK showed uptrend with time and
were higher than those of group CIK except for preloading and the
6-hour point. K-ras-DCCIK DCCIK versus CIK after 12h,
∗P <
0.01. K-ras-DCCIK versus DCCIK after 12h, P<0.05. But the
expression in group CIK showed no apparent increase (Figures 2(a)
and 2(b)).
proliferation sped up on the sixth day with the cell popula-
tion increasing noticeably. When cultured for 14 days, pro-
liferation capacity of K-ras-DCCIK was remarkably greater
than that of other groups (P<0.01). DCCIK proliferation
was also greater than CIK (P<0.05) (Figure 4). This showed
that K-ras-DC can stimulate the proliferation of CIK eﬀec-
tively. After being allergized by peptide antigen, the DC’s as-
cending secretion of IFN-γ and IL-12 further stimulated the
CIK’s proliferation.Clinical and Developmental Immunology 5
A BC
Fascin-1
β-actin
Figure 3: The fascin-1 and β-actin protein expression of DCCIK
CIK and K-ras-DCCIK by western blot (experiment 2.6). A, B, and
C demonstrate the fascin-1 expression in DCCIK, CIK, and K-ras-
DCCIK cultured for 14 days. Compared with group DCCIK and
CIK, fascin-1 in K-ras-DCCIK was increasing signiﬁcantly (P<
0.01). DCCIK versus CIK has statistical signiﬁcance (P<0.05). The
gray values of the reference protein bands are almost equal. It was
shown that β-actin can be stably expressed in the cells.
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Figure 4: The proliferation activity of CIK cultured with K-ras
antigen-pulsed DC (experiment 2.3, 2.4). When cultured for 14
days,proliferationcapacityofK-ras-DCCIKwasremarkablygreater
than other groups (
∗P < 0.01). And DCCIK proliferation was
also greater than CIK ( ΔP < 0.05). It is proved that K-ras-DC can
stimulate the proliferation of CIK eﬀectively.
3.5. Detection of Cytokine, IL-12 and IFN-γ. In the superna-
tant of group K-ras-DCCIK cultured for 14 days, IFN-γ
and IL-12 levels were higher than those of group CIK and
group DCCIK (P<0.01). And IFN-γ and IL-12 levels in the
supernatant of group DCCIK were also higher than those of
group CIK (P<0.05. After coculture of CIKs and DCs, IFN-
γ and IL-12 levels in the cell supernatants can be increas-
ed. Furthermore, the antineoplastic activity of the speciﬁc
antigen-pulsed DCCIK became stronger (Figure 5).
3.6. Detection for Killing Activity of CIK and CTL to PANC-
1 and SW1990 Pancreatic Cancer Cell In Vitro. The K-ras-
DCCIKs, DCCIKs, CIKs, and CTLs induced by K-ras pulsed
DC sw e r eu s e da se ﬀector cells, and the pancreatic cancer cell
strains, PANC-1 and SW1990, were used as target cells. The
diﬀerentkillingeﬀectsoftheCIKgroupsonPANC-1showed
that the killing rate of group K-ras-DCCIK was greatest and
signiﬁcantly exceeded group CIK and group CTL (P<0.01).
However, there was no diﬀerence between group CIK and
group CTL (P>0.05). After increasing the eﬀector-target
ratio, the killing rates of the eﬀector cells against the pan-
creatic cancer cells in all the groups also became higher
(Figure 6(a)). As the diﬀerent killing eﬀects of the CIKs
groups on SW1990 demonstrated K-ras-DCCIKs, DCCIKs,
and CIKs, all showed their killing eﬀects on SW1990 cells,
and their killing rates are higher than group CTL (P<0.01).
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Figure 5 :T h ep r o d u c t i o no fI L - 1 2a n dI F N - γ of CIK cultured with
K-ras antigen-pulsed DC (experiment 2.4). In the supernatant of
group K-ras-DCCIK cultured for 14 days, IFN-γ and IL-12 levels
were highest, K-ras-DCCIK versus DCCIK and CIK (
∗P < 0.01).
And levels in group DCCIK were also higher than those of CIK
( ΔP < 0.05). It is demonstrated that after coculture of CIKs and
k-ras-DCs, IFN-γ and IL-12 levels in the cell supernatants can be
apparently increased.
ButthecomparisonofthekillingeﬀectbetweengroupK-ras-
DCCIK and group DCCIK showed no statistical signiﬁcance
(P>0.05) (Figure 6(b)).
By testing the in vitro killing inhibitions of K-ras-
DCCIKs to PANC-1 (K-ras+) and SW1990 (K-ras−), it was
found that, when eﬀector-target ratio reached 1:12.5 and
1:25, K-ras-DCCIKs’ inhibition to PANC-1 was stronger
than that to SW1990 (P<0.05). However, eﬀector-target ra-
tio increased to 1:50; K-ras-DCCIKs’ inhibition to these two
cells showed no statistical diﬀerence (P>0.05) (Figure 7).
3.7. The Eﬀects of Various CIKs and CTL on Survival Time
of Tumor-Bearing Nude Mice Loading PANC-1 and SW1990
Pancreatic Cancer Cells. 2 × 106 cells of CIK groups and
k-ras-DC-induced CTL group were injected intratumorly
into the tumor-bearing nude mice, and their eﬀects on the
mice survival time were investigated. Concerning the eﬀects
on the survival time of PANC-1 (K-ras+) tumor-bearing
mice (Figure 8(a)), the survival time of group K-ras-DCCIK
was prolonged remarkably. There is signiﬁcant diﬀerence
in comparison with other groups (P<0.01). In group
DCCIK, group CIK, and group CTL, the mice survival times
were extended correspondingly. But there were no statistical
diﬀerences among the groups (P>0.05). It is demonstrated
that the DC-induced speciﬁc CTL can inhibit PANC-1.
Meanwhile, K-ras-DCCIK can produce speciﬁc and imme-
diate killing eﬀect on PANC-1. This will lead to prolonged
survival time. Concerning the eﬀects on the survival time of
SW1900(K-ras−)tumor-bearingmice(Figure 8(b)),thesur-
vival time of group K-ras-DCCIK, group DCCIK, and group
CIK was elongated dramatically. Also, compared with group
CTL, the diﬀerence has statistical signiﬁcance (P<0.01).6 Clinical and Developmental Immunology
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Figure 6: The cytotoxicity of K-ras-DCCIK, DCCIK, CIK, and
CTL induced by K-ras pulsed DC against PANC-1 (K-ras+)a n d
SW1990 (K-ras−) cells in vitro (experiment 2.7). The K-ras-
DCCIKs, DCCIKs, CIKs, and CTLs induced by K-ras pulsed DCs
used as eﬀector cells. PANC-1 and SW1990 used as target cells. The
killing eﬀects on PANC-1 showed that group K-ras-DCCIK exceed-
e dg r o u pC I Ka n dg r o u pC T Lr e m a r k a b l y( P<0.01). However,
there was no diﬀerence between group CIK and CTL (P>0.05),
(Figure 6(a)).The diﬀerent killing eﬀects on SW1990 demonstrated
K-ras-DCCIKs, DCCIKs, and CIKs; all showed their killing eﬀects
on SW1990 cells and are higher than CTL (P<0.01), (Figure 6(b)).
However, there were still no signiﬁcant diﬀerences among
the groups (P>0.05). It is shown that to varying degrees,
the CIK groups possess the direct inhibition to SW1900. In
contrast, the speciﬁc CTL induced by K-ras mutant peptide-
pulsed DC showed the lower inhibition to K-ras mutation-
negative cell, SW1900. In group CTL, the survival time of the
SW1900 tumor-bearing mice was not extended.
4. Discussions
Tumorigenesis is a sustained process of gene mutations.
Almoguera et al. [11] ﬁrst reported the point mutation of
K-ras gene in pancreatic cancer suﬀerers. Since, it had been
investigated that, in 85%–95% of pancreatic cancer patients,
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Figure 7: The cytotoxicity of K-ras-DCCIK against PANC-1 (K-
ras+) and SW1990 (K-ras−)c e l l sa td i ﬀerent E : T ratio in vitro
(experiment 2.7). It was found that when eﬀector-target ratio
reached 1:12.5 and 1:25, K-ras-DCCIKs’ inhibition to PANC-1
wasstrongerthanthattoSW1990(
∗P < 0.05).However, E : T ratio
at 1:6.25 and 1:50, K-ras-DCCIKs’ inhibition to these two cells
showed no statistical diﬀerence ( ΔP > 0.05). It is demonstrated that
CIK cells have a potential to uptake tumor antigens, and further,
to produce speciﬁc killing eﬀect on PANC-1, there might be some
antigen-speciﬁc CTL cell subsets existing in K-ras-DCCIKs.
K-ras gene mutations occurred and almost all the mutations
happened at the 12th codon. Hence, the 12th mutational site
of K-ras protein can be used as a potential site for gene im-
munotherapy of pancreatic cancer [12, 13]. Nakada et al.
[14] and others had used the antisense oligonucleotides for
K-ras gene mutations to transfect the pancreatic cancer cell,
PANC-1. This treatment can inhibit the mRNA expression of
K-ras gene and the synthesis of ras protein. Thus, it can sup-
press the growth of pancreatic cancer cell and facilitate the
apoptosis of cancer cells. He et al. [15] and others had tried
to use K-ras mutated peptide to modify DCs in order to ac-
tivate T cells. It had been found that DCs can present K-ras
mutatedsiteseﬀectively.Inthisstudy,weusedK-rasmutated
peptide to modify DCs. After coculture with the modiﬁed
DCs, CIKs showed immediate and speciﬁc inhibition to pan-
creatic cancer cells in vitro and in vivo.
CIKs is a cell population obtained from human periph-
eral blood mononuclear cells stimulated with IFN-γ,I L - 2 ,
and CD3 monoclonal antibody (OKT3). They can express
the surface markers of T cells and NK cells, CD3+CD56+
[16]. For now, CIK is known to have the fastest proliferation,
the strongest tumor cytotoxicity, and the most extensive
range of tumor killing [17]. CIKs’ killing action to tumors
is via recognition of a series of associated ligands on tumor
cell surfaces, though not only depending upon one antigen
[5]. CIKs can both directly inhibit tumor cells and regulate
immune system of body to kill tumor cells indirectly [18].
Therefore, they can suppress the tumor’s growth and recur-
rence by immediate inhibition to tumor cells and improve
the immunity of patients for long-term eﬀect [19]. CIKs sel-
dom arouse graft-versus-host disease (GVHD) and are safe
and eﬀective for patients who had developed drug resistance.Clinical and Developmental Immunology 7
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Figure 8: Survival of nude mice inoculated subcutaneously in
the back with PANC-1 (K-ras+) and SW1990(K-ras−)c e l l sa f t e r
immunotherapy with CTLs and diﬀerent CIKs (experiment 2.8)
concerning the eﬀects on the survival time of PANC-1 (K-ras+)
tumor-bearingmice(Figure 8(a)),thesurvivaltimeofgroupK-ras-
DCCIK was prolonged remarkably, compared with other groups
(P<0.01). No statistical diﬀerence was found among the group
DCCIK, CIK and CTL (P>0.05). It is demonstrated that the
k-ras-DC induced CTL can inhibit PANC-1. Meanwhile, K-ras-
DCCIKcanproducespeciﬁcandimmediatekillingeﬀectonPANC-
1. Concerning the eﬀects on the survival time of SW1900 (K-ras−)
tumor-bearingmice(Figure 8(b)),thesurvivaltimeofgroupK-ras-
DCCIK, DCCIK and CIK was elongated dramatically. Compared
with group CTL (P<0.01). The CIK groups possess the direct
inhibition to SW1900. The CTL induced by K-ras-DC showed the
lower inhibition to K-ras mutation negative cell, SW1900. Thus, the
survival time of the SW1900 tumor-bearing mice was not extended.
Coculture of CIKs with DCs can increase their proliferation
activity and cytotoxicity [20]. At present, the mechanism of
why DCs can enhance CIKs’ killing activity is still unclear.
It has been speculated that the strengthened tumor-killing
eﬀect of DCCIKs may be associated with upregulation of
cytokines, such as IL-12 and IFN-γ, in DCCIKs’ supernatant
and with high expression of CD3+CD56+ double positive
c e l l sa sw e l l[ 21]. In this study, by testing the expressions of
DCs’ surface molecules, the results show that K-ras mutat-
ed peptide can promote DCs’ mature and facilitate eﬀective
presentation of speciﬁc antigens [22]. IFN-γ and IL-12 levels
of group K-ras-DCCIK are highest, superior to those of
group DCCIK and group CIK remarkably (P<0.01). More-
over, after co-cultivation, K-ras-DCCIKs highly expressed
CD3+CD8+ and CD3+CD56+, exceeding those of group CIK
signiﬁcantly (P<0.05).
The chemokine, CCL19, is expressed in secondary lym-
phoid organs and thymus. It can urge DCs to migrate from
peripheral region to T-cell accumulation area in lymph-
oid organs and induce Th1 and T cells to make an immune
response [23–25]. CCL22 is expressed in the spleen, periph-
eral blood T cells, NK cells, and so on. [26]. In the super-
natant of the monocyte-derived DCs, intact CCL22 become
highly expressed and produce intense chemotaxis for DCs
[27, 28]. In ELISA test for CCL19 and CCL22 of various
CIK groups, it was founded that k-ras-DCs can apparently
enhanceCIKs’migrationactivityandcanimprovetheirmig-
ration capacity towards tumor cells. These actions provide
some necessary conditions for increasing killing activity and
suppressing tumor growth. In immune system, Fascin-1
protein is only expressed in the mature DCs and related
to DCs’ movements [29, 30]. The research indicated that
the secretory volume of k-ras-DCCIKs’ cytoskeletal protein
Fascin-1 was increased remarkably. Compared with group
DCCIK and group CIK, the increasing has dramatically sta-
tistical signiﬁcance (P<0.01). It was demonstrated that K-
ras mutated peptide can induce DCs’ mature and enhance
k-ras-DCCIKs’ migrating capacity.
k-ras-DCCIKs’ proliferation capacity is signiﬁcantly
higher than that of other groups (P<0.01). It can be seen
that k-ras-DC can eﬀectively stimulate CIKs’ proliferation.
Moreover, the increased secretion of IFN-γ and IL-12 further
irritated CIKs’ proliferation. Marten and so forth [31] used
CA19-9 antigen-pulsed mature DCs and antigen peptide-
untreated DCs to coculture with CIKs. In contrast with
untreated DCs group, the former showed increased killing
activity. It was prompted that, in the CIKs cocultured with
CA19-9 pulsed DCs, there were existing antigen-speciﬁc
CTL subsets. In our in vitro experiment, the killing activity
of K-ras-DCCIK group to PANC-1 cells was also superior
to those of CIK group and k-ras-DC-induced CTL group
(P<0.01). It indicates that, via K-ras pulsing, the DCs
further enhanced CIKs’ killing activity. Compared with k-
ras-DC-induced speciﬁc CTLs, CIKs have almost identical
killing eﬃciency (P>0.05). The speciﬁc CTLs have obvious
inhibition to K-ras+ PANC-1, while K-ras-DCCIKs have
immediate PANC-1 killing eﬀect, which is speciﬁc and
more remarkable so as to make the mice’s survival period
signiﬁcantly prolonged. All of the K-ras-DCCIKs, DCCIKs,
and CIKs showed inhibitions to SW1990 cells. But k-ras-
DC-inducedspeciﬁcCTLspresenttheweakenedsuppression
towards SW1990 cells. Compared with DCCIKs’ inhibition,
there is a signiﬁcant statistical diﬀerence (P<0.01). It was
shown that, to varying degrees, the CIK groups possess the
direct inhibition to SW1900. In contrast, the speciﬁc CTLs
showed the lower inhibition to K-ras mutation-negative cell,
SW1900. In group CTL, the survival time of the SW1900
tumor-bearing mice was not extended. In this study, by co-
culturing tumor antigen-pulsed DCs with CIKs, we obtained8 Clinical and Developmental Immunology
thek-ras-DCCIKs,whichhavemoreprominentoncotherapy
eﬀect and more powerful tumor inhibition than CIKs and
show a favourable application prospect.
PANC-1 and SW1990 cells were inhibited with k-ras-
DCCIK separately. The results show that, when eﬀector-
target ratio reached 1:12.5 and 1:25, K-ras-DCCIKs can
produce speciﬁc inhibition to PANC-1. Further, the killing
eﬃciencies towards these two pancreatic cancer cells have
statisticaldiﬀerence(P<0.05).However,increasingeﬀector-
target ratio, the diﬀerence of speciﬁc tumor inhibition for
these two cells showed no statistical signiﬁcance (P>0.05).
It is demonstrated that CIK cells have a potential to uptake
tumor antigens and further to produce speciﬁc killing eﬀect
on cancer cells. In K-ras-DCCIKs, there might be some anti-
gen-speciﬁc CTL cell subsets existing. Allergization for CIKs
with tumor antigen-pulsed DCs can both exert non-MHC
restrictive cytotoxicity of CIKs and activate MHC restrictive
cytotoxicity mediated by antigen-pulsed DCs to strengthen
the speciﬁc killing eﬀect on speciﬁc target cells [32]. How-
ever, when eﬀector-target ratio is high, it might be CIKs’
strong tumor direct killing eﬀect that covers their speciﬁc ac-
tion. This phenomenon is to be further investigated in the
future.
In conclusion, the results demonstrate that, after being
pulsed with K-ras, DCs can enhance CIKs’ proliferation and
migration capacities, and can enhance killing activity against
pancreatic cancer cells as well. Moreover, CIKs’ enhanced
killing activity may be associated with upregulation of IFN-γ
and IL-12 in supernatants and high expression of double-
positive cells CD3+CD8+ and CD3+CD56+.T h ea n t i g e n -
allergized DCCIKs can produce in vitro killing activity spe-
ciﬁc to tumor cells. Their pertinence of tumor suppression is
almost the same as with the speciﬁc CTLs, while their total
tumor inhibitory eﬃciency is higher than the CTLs.
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